A Phase 2 Study of Nivolumab and Ipilimumab Immunotherapy With or Without Cabozantinib for Advanced Nasopharyngeal Cancer


Full Title

Randomized Phase 2 Study of Nivolumab and Ipilimumab with or Without Cabozantinib in Patients with Advanced Nasopharyngeal Carcinoma That Have Progressed After Platinum Treatment and Immunotherapy (A092105) (CIRB)


Researchers are assessing nivolumab and ipilimumab immunotherapy with or without cabozantinib to treat advanced nasopharyngeal cancer. The people in this study have nasopharyngeal cancer that recurred (came back) or metastasized (spread). In addition, the cancer cannot be cured with other therapies.

Nivolumab and ipilimumab take the brakes off the immune response, enabling immune cells to find and kill cancer cells. They are both given intravenously (by vein). Cabozantinib blocks the action of an abnormal protein that tells cancer cells to multiply. It is taken orally (by mouth).

If you join this study, you will be randomly assigned to get nivolumab and ipilimumab with or without cabozantinib.

Who Can Join

To join this study, there are a few conditions. You must:

  • Have recurrent or metastatic nasopharyngeal cancer that keeps growing after no more than 2 prior regimens of treatment.
  • Have completed previous therapies at least 4 weeks before getting the study treatment.
  • Be able to walk and do routine activities for more than half the time you are awake.
  • Be age 18 or older.


For more information and to see if you can join this study, please call Dr. Eric Sherman’s office at 646-608-3776.




Phase II (phase 2)



ClinicalTrials.gov ID